Sheet

PTO/SB/08a (08-03)

UCI 8 0 3002 Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE operwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

for form 1449A/PTO HADEM

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/774,903 Filing Date February 10, 2004 First Named Inventor Ekwuribe, Nnochiri N. Art Unit 1654 Jeffrey E. Russell **Examiner Name** 014811-189.74CT Attorney Docket Number

			U.S. PATENT D	OCUMENTS	
Examiner Initials'	Cite No.1	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JAR	B1	US- 2003/0153488 a1	08/14/2003	May et al.	
1	B2	US- 2003/0060608 A1	03/27/2003	Ekwuribe et al.	
	В3	US- 6,506,730 B1	01/14/2003	Lee et al.	
	B4	US- 5,773,581	08/30/1998	Camble et al.	
	B5 ·	US- 5,108,568	04/28/1992	Van Alstine	
	B 6	US- 4,526,938	07/02/1985	Churchill et al.	
		US-			
		US-			
_		US-			
		US-			· · · · · · · · · · · · · · · · · · ·
		US-			

2

of

FOREIGN PATENT DOCUMENTS					CUMENTS		
Exan i Initia		Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
•		87	WO 2003/022996 A3	03/20/2003	Nobex Corporation		
		88	WO 2003/022996 A2	03/20/2003	Nobex Corporation		
\neg	\neg	B9	WO 03 022210 A3	03/20/2003	Nobex Corporation .		
		B10	WO 03/022210 A2	03/20/2003	Nobex Corporation		
		B11	· WO 03/022208 A3	03/20/2003	Nobex Corporation		
		B12	WO 03/022208 A2	03/20/2003	Nobex Corporation		
		B13	WO 02/098446 A1	12/12/2002	Nobex Corporation		_
		B14	WO 02/098232 A1	12/12/2002	Nobex Corporation		
	_	B15	WO 00/78302 A1	12/28/2000	Protein Delivery Inc.		
		B16	WO 00/43034 A3	07/27/2000	Ell Lilly and Company		<u>├</u>
		B17	WO 00/43034	07/27/2000	Eii Lilly and Company		
	\neg	B18	EP 0 381 070 A1	08/08/1990	Farmhispania S.A.		
		B19	EP 0 354 855 B1	02/14/1990	Terumo Kabushiki Kaisha		
7	7	820	EP 0 092 918 B1	11/02/1983	Imperial Chemical Industries PLC		

Examiner		Date	
Signature	/James Reagan/ (07/24/2006)	Considered	
0.5	/ * * * * * * * * * * * * * * * * * * *	CONSIDERED	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 8 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 08/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

					Complete if Known	
Substitute for form 1449B/PTO				Application Number	10/77 ,903	
SECOND SUPPLEMENTAL				Filing Date	February 10, 2004	
INFORMATION DISCLOSURE				First Named Inventor	Ekwuribe, Nnochiri N.	
	TATEMENT BY			Art Unit	1654	
				Examiner Name	Jeffrey E. Russell	
(use as many sheets as necessary)						_
Sheet	2	of	2	Attorney Docket Number	014811-189.74CT	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
JAR	B21	SAMUEL ZALIPSKY; Synthesis of an End-Group Functionalized Polyethylene Glycol-Lipid Conjugate for Preparation of Polymer-Grafted Liposomes; Bloconjugate Chemistry; 1993; No. 4, pp. 296-299; American Chemical Society	
	B22	KANG CHOON LEE et al.; Isolation, Characterization, and Stability of Positional Isomers of Mono-PEGylated Salmon Calcitonins; Pharmaceutical Research; 1999; Vol. 16, No. 6, pp. 813-818; Plenum Publishing Corporation	
	B23	HAESHIN LEE et al.; Preparation and Characterization of Mono-PEGylated Epidermal Growth Factor: Evaluation of <i>in Vitro</i> Biologic Activity; Pharmaceutical Research; 2002; Vol. 19, No. 6, pp. 845-851; Plenum Publishing Corporation	
	B24	ANDREA LUCKE et al.; Biodegradable poly(D,L-lactic acid)-poly(ethylene glycol)-monomethyl ether dlblock copolymers: structures and surface properties relevant to their use as biomaterials; Biomaterials; 2000; 21, pp. 2361-2370; Elsevier Science Ltd.	
V	B25	JONG-HOON LEE et al.; Polymeric nanoparticle composed of fatty acids and poly(ethylene glycol) as a drug carrier; International Journal of Pharmaceutics; 2003; 251, pp. 23-32; Elsevier Science B.V.	
·			
·			

Signature / James Reagan/ (07/24/2006) Considered	Examiner Signature	/James Reagan/ (07/24/2006)	Date Considered
---	-----------------------	-----------------------------	--------------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03) Approved for use through 07/31/2006, OMB 0651-0031

Under the Paperwork Reduction Act of 1895, no pers	n of beniupar ana eno	U,Ş, Palant and Trader apond to a pallaction o <u>f informat</u>	nani Office; U.Ş, DEPAR) tlog upjesa it cogtains a vi	rment of commerce <u>and OMB control number.</u>	
Substitute for form 1449/PTO		Col	mplete if Known		
Supplement of form 1444-210		Application Number	10/771,903	RECE	IVED
INFORMATION DISCLOSURI		Filing Date	2/4/2004	CENTRAL F	AX CENTER
		First Named Inventor	Fisher et al		
STATEMENT BY APPLICANT		Art Unit	2650	FEB 0	1 2005
(Use as many sheets as necessary)	:	Examiner Name			l
Chant 11 of 11		Attorney Docket Number	sony-05800		

	-		U. S. PATENT	BOCUMENTS	
Examiner Indals*	Cite No.'	Document Number Number-Kind Cods ^{2 (f knowl)}	Publication Date	Name of Patentoe or Applicant of Citod Document	Pagos, Columns, Lines, Where Relevant Pessages or Relevant Figures Appear
JAR		^{US-} 6,453,053	9-17-2002	Wakasu	
MA	\Box	^{us.} 6,592,033	7-15-2003	Jennings et al	
Λ		us- 5,926,557	7-20-1999	King et al	
		US-			
		US-			
		US-			
		UŠ-			
		US-			
		บร-			
		U\$-			
		US-			
		US-			
		uā-			
	1	US-			
-		US-			
		US-			
	\top	US-			
	1	US-			
	1	US-		1	

Exeminer	Cite	Foreign Petant Document	IGN PATENT DOCU	Name of Patentee or	Pages, Columns, Unes,	г
nitials"	No.3		Date	Applicant of Cited Document	Where Relevant Passages	l
		Country Codo ² "Number ⁴ " Kind Codo ⁵ (if known)	MM-DD-YYYY		Or fletevant Figures Appear	Ľ
						L
						I
						I
						T
						۲

Exeminer Signature	/James Reagan/ (07/24/2006)	Considered

EXAMINER: United in reservance considered, whether or not citation is in conformance with MPEP 800. Draw line through district in conformance and not considered, include copy of this form with next communication to applicant. Applicants unique citation designation number (apidana). See Kinds Codes at USPTO Patent Documents at www.uceris.agu or MPEP 801.04. Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). For Japanese patent documents, this indication of the year of the retire of the Standard ST.30. For appropriate symbols as indicated on the document under WIPO Standard ST.10 if possible. Applicant is to place a check monk hore if English longuage Translation is attached.

Translation is stacked.
This collection of information is required by 37 CFR 1,97 and 1,98. The intermation is required to obtain or retain a banefit by the public which is to file (and by the USPTO to process) an application. Commonitoring is governed by 35 U.S.C. 122 and 37 GFR 1,14. This extinction is esometrial to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the ISPTO. Time will vary depending upon the britishing the complete this form and/or suggestions for enduring this burden, should be sent to the Chief Information Officer, U.S. Patoni and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADORESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If your mend assistance in complaining the firm, cell 1-800-PTO-8199 (1-800-786-9199) and select option 2.